カテゴリー： QYResearch, 世界, 医療/バイオ

世界のオミクス系臨床試験市場インサイト及び予測（介入研究、観察研究、拡張アクセス研究）

◆英語タイトル：Global Omics Based Clinical Trials Market Insights, Forecast to 2028
	◆商品コード：QY22JLX09264 ◆発行会社（リサーチ会社）：QYResearch ◆発行日：2022年7月（※2025年版があります。お問い合わせください。） ◆ページ数：105 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後3営業日） ◆調査対象地域：グローバル ◆産業分野：医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD4,900 ⇒換算￥744,800	見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）	USD7,350 ⇒換算￥1,117,200	見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）	USD9,800 ⇒換算￥1,489,600	見積依頼/購入/質問フォーム

★QYResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、オミクス系臨床試験のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にオミクス系臨床試験の世界市場のxxx％を占める「介入研究」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「腫瘍」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
オミクス系臨床試験の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのオミクス系臨床試験市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

オミクス系臨床試験のグローバル主要企業には、Parexel International Corporation、Pharmaceutical Product Development (PPD)、Charles River Laboratory、ICON plc、SGS SA、Eli Lilly and Company、Pfizer、Covance、Rebus Bio、Novo Nordiskなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

オミクス系臨床試験市場は、種類と用途によって区分されます。世界のオミクス系臨床試験市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
介入研究、観察研究、拡張アクセス研究

【用途別セグメント】
腫瘍、心臓病、呼吸器疾患、皮膚病、CNS疾患、免疫、遺伝病、その他

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- オミクス系臨床試験製品概要
- 種類別市場（介入研究、観察研究、拡張アクセス研究）
- 用途別市場（腫瘍、心臓病、呼吸器疾患、皮膚病、CNS疾患、免疫、遺伝病、その他）
- 調査の目的
・エグゼクティブサマリー
- 世界のオミクス系臨床試験販売量予測2017-2028
- 世界のオミクス系臨床試験売上予測2017-2028
- オミクス系臨床試験の地域別販売量
- オミクス系臨床試験の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別オミクス系臨床試験販売量
- 主要メーカー別オミクス系臨床試験売上
- 主要メーカー別オミクス系臨床試験価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（介入研究、観察研究、拡張アクセス研究）
- オミクス系臨床試験の種類別販売量
- オミクス系臨床試験の種類別売上
- オミクス系臨床試験の種類別価格
・用途別市場規模（腫瘍、心臓病、呼吸器疾患、皮膚病、CNS疾患、免疫、遺伝病、その他）
- オミクス系臨床試験の用途別販売量
- オミクス系臨床試験の用途別売上
- オミクス系臨床試験の用途別価格
・北米市場
- 北米のオミクス系臨床試験市場規模（種類別、用途別）
- 主要国別のオミクス系臨床試験市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパのオミクス系臨床試験市場規模（種類別、用途別）
- 主要国別のオミクス系臨床試験市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋のオミクス系臨床試験市場規模（種類別、用途別）
- 主要国別のオミクス系臨床試験市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米のオミクス系臨床試験市場規模（種類別、用途別）
- 主要国別のオミクス系臨床試験市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカのオミクス系臨床試験市場規模（種類別、用途別）
- 主要国別のオミクス系臨床試験市場規模（トルコ、サウジアラビア）
・企業情報
Parexel International Corporation、Pharmaceutical Product Development (PPD)、Charles River Laboratory、ICON plc、SGS SA、Eli Lilly and Company、Pfizer、Covance、Rebus Bio、Novo Nordisk
・産業チェーン及び販売チャネル分析
- オミクス系臨床試験の産業チェーン分析
- オミクス系臨床試験の原材料
- オミクス系臨床試験の生産プロセス
- オミクス系臨床試験の販売及びマーケティング
- オミクス系臨床試験の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- オミクス系臨床試験の産業動向
- オミクス系臨床試験のマーケットドライバー
- オミクス系臨床試験の課題
- オミクス系臨床試験の阻害要因
・主な調査結果

Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics.Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.
Market Analysis and Insights: Global Omics Based Clinical Trials Market
The global Omics Based Clinical Trials market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Interventional Studies accounting for % of the Omics Based Clinical Trials global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Oncology segment is altered to an % CAGR throughout this forecast period.
China Omics Based Clinical Trials market size is valued at US$ million in 2021, while the North America and Europe Omics Based Clinical Trials are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Omics Based Clinical Trials landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Omics Based Clinical Trials market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Omics Based Clinical Trials market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Omics Based Clinical Trials market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Omics Based Clinical Trials market.
Global Omics Based Clinical Trials Scope and Market Size
Omics Based Clinical Trials market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Omics Based Clinical Trials market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Interventional Studies
Observational Studies
Expanded Access Studies
Segment by Application
Oncology
Cardiology
Respiratory Diseases
Skin Diseases
CNS Diseases
Immunology
Genetic Diseases
Other Indications
By Company
Parexel International Corporation
Pharmaceutical Product Development (PPD)
Charles River Laboratory
ICON plc
SGS SA
Eli Lilly and Company
Pfizer
Covance
Rebus Bio
Novo Nordisk
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

❖ レポートの目次 ❖

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Omics Based Clinical Trials Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Interventional Studies
1.2.3 Observational Studies
1.2.4 Expanded Access Studies
1.3 Market by Application
1.3.1 Global Omics Based Clinical Trials Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Respiratory Diseases
1.3.5 Skin Diseases
1.3.6 CNS Diseases
1.3.7 Immunology
1.3.8 Genetic Diseases
1.3.9 Other Indications
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Omics Based Clinical Trials Market Perspective (2017-2028)
2.2 Omics Based Clinical Trials Growth Trends by Region
2.2.1 Omics Based Clinical Trials Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Omics Based Clinical Trials Historic Market Size by Region (2017-2022)
2.2.3 Omics Based Clinical Trials Forecasted Market Size by Region (2023-2028)
2.3 Omics Based Clinical Trials Market Dynamics
2.3.1 Omics Based Clinical Trials Industry Trends
2.3.2 Omics Based Clinical Trials Market Drivers
2.3.3 Omics Based Clinical Trials Market Challenges
2.3.4 Omics Based Clinical Trials Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Omics Based Clinical Trials Players by Revenue
3.1.1 Global Top Omics Based Clinical Trials Players by Revenue (2017-2022)
3.1.2 Global Omics Based Clinical Trials Revenue Market Share by Players (2017-2022)
3.2 Global Omics Based Clinical Trials Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Omics Based Clinical Trials Revenue
3.4 Global Omics Based Clinical Trials Market Concentration Ratio
3.4.1 Global Omics Based Clinical Trials Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Omics Based Clinical Trials Revenue in 2021
3.5 Omics Based Clinical Trials Key Players Head office and Area Served
3.6 Key Players Omics Based Clinical Trials Product Solution and Service
3.7 Date of Enter into Omics Based Clinical Trials Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Omics Based Clinical Trials Breakdown Data by Type
4.1 Global Omics Based Clinical Trials Historic Market Size by Type (2017-2022)
4.2 Global Omics Based Clinical Trials Forecasted Market Size by Type (2023-2028)
5 Omics Based Clinical Trials Breakdown Data by Application
5.1 Global Omics Based Clinical Trials Historic Market Size by Application (2017-2022)
5.2 Global Omics Based Clinical Trials Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Omics Based Clinical Trials Market Size (2017-2028)
6.2 North America Omics Based Clinical Trials Market Size by Type
6.2.1 North America Omics Based Clinical Trials Market Size by Type (2017-2022)
6.2.2 North America Omics Based Clinical Trials Market Size by Type (2023-2028)
6.2.3 North America Omics Based Clinical Trials Market Share by Type (2017-2028)
6.3 North America Omics Based Clinical Trials Market Size by Application
6.3.1 North America Omics Based Clinical Trials Market Size by Application (2017-2022)
6.3.2 North America Omics Based Clinical Trials Market Size by Application (2023-2028)
6.3.3 North America Omics Based Clinical Trials Market Share by Application (2017-2028)
6.4 North America Omics Based Clinical Trials Market Size by Country
6.4.1 North America Omics Based Clinical Trials Market Size by Country (2017-2022)
6.4.2 North America Omics Based Clinical Trials Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Omics Based Clinical Trials Market Size (2017-2028)
7.2 Europe Omics Based Clinical Trials Market Size by Type
7.2.1 Europe Omics Based Clinical Trials Market Size by Type (2017-2022)
7.2.2 Europe Omics Based Clinical Trials Market Size by Type (2023-2028)
7.2.3 Europe Omics Based Clinical Trials Market Share by Type (2017-2028)
7.3 Europe Omics Based Clinical Trials Market Size by Application
7.3.1 Europe Omics Based Clinical Trials Market Size by Application (2017-2022)
7.3.2 Europe Omics Based Clinical Trials Market Size by Application (2023-2028)
7.3.3 Europe Omics Based Clinical Trials Market Share by Application (2017-2028)
7.4 Europe Omics Based Clinical Trials Market Size by Country
7.4.1 Europe Omics Based Clinical Trials Market Size by Country (2017-2022)
7.4.2 Europe Omics Based Clinical Trials Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Omics Based Clinical Trials Market Size (2017-2028)
8.2 Asia-Pacific Omics Based Clinical Trials Market Size by Type
8.2.1 Asia-Pacific Omics Based Clinical Trials Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Omics Based Clinical Trials Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Omics Based Clinical Trials Market Share by Type (2017-2028)
8.3 Asia-Pacific Omics Based Clinical Trials Market Size by Application
8.3.1 Asia-Pacific Omics Based Clinical Trials Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Omics Based Clinical Trials Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Omics Based Clinical Trials Market Share by Application (2017-2028)
8.4 Asia-Pacific Omics Based Clinical Trials Market Size by Region
8.4.1 Asia-Pacific Omics Based Clinical Trials Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Omics Based Clinical Trials Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Omics Based Clinical Trials Market Size (2017-2028)
9.2 Latin America Omics Based Clinical Trials Market Size by Type
9.2.1 Latin America Omics Based Clinical Trials Market Size by Type (2017-2022)
9.2.2 Latin America Omics Based Clinical Trials Market Size by Type (2023-2028)
9.2.3 Latin America Omics Based Clinical Trials Market Share by Type (2017-2028)
9.3 Latin America Omics Based Clinical Trials Market Size by Application
9.3.1 Latin America Omics Based Clinical Trials Market Size by Application (2017-2022)
9.3.2 Latin America Omics Based Clinical Trials Market Size by Application (2023-2028)
9.3.3 Latin America Omics Based Clinical Trials Market Share by Application (2017-2028)
9.4 Latin America Omics Based Clinical Trials Market Size by Country
9.4.1 Latin America Omics Based Clinical Trials Market Size by Country (2017-2022)
9.4.2 Latin America Omics Based Clinical Trials Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Omics Based Clinical Trials Market Size (2017-2028)
10.2 Middle East & Africa Omics Based Clinical Trials Market Size by Type
10.2.1 Middle East & Africa Omics Based Clinical Trials Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Omics Based Clinical Trials Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Omics Based Clinical Trials Market Share by Type (2017-2028)
10.3 Middle East & Africa Omics Based Clinical Trials Market Size by Application
10.3.1 Middle East & Africa Omics Based Clinical Trials Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Omics Based Clinical Trials Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Omics Based Clinical Trials Market Share by Application (2017-2028)
10.4 Middle East & Africa Omics Based Clinical Trials Market Size by Country
10.4.1 Middle East & Africa Omics Based Clinical Trials Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Omics Based Clinical Trials Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Parexel International Corporation
11.1.1 Parexel International Corporation Company Details
11.1.2 Parexel International Corporation Business Overview
11.1.3 Parexel International Corporation Omics Based Clinical Trials Introduction
11.1.4 Parexel International Corporation Revenue in Omics Based Clinical Trials Business (2017-2022)
11.1.5 Parexel International Corporation Recent Developments
11.2 Pharmaceutical Product Development (PPD)
11.2.1 Pharmaceutical Product Development (PPD) Company Details
11.2.2 Pharmaceutical Product Development (PPD) Business Overview
11.2.3 Pharmaceutical Product Development (PPD) Omics Based Clinical Trials Introduction
11.2.4 Pharmaceutical Product Development (PPD) Revenue in Omics Based Clinical Trials Business (2017-2022)
11.2.5 Pharmaceutical Product Development (PPD) Recent Developments
11.3 Charles River Laboratory
11.3.1 Charles River Laboratory Company Details
11.3.2 Charles River Laboratory Business Overview
11.3.3 Charles River Laboratory Omics Based Clinical Trials Introduction
11.3.4 Charles River Laboratory Revenue in Omics Based Clinical Trials Business (2017-2022)
11.3.5 Charles River Laboratory Recent Developments
11.4 ICON plc
11.4.1 ICON plc Company Details
11.4.2 ICON plc Business Overview
11.4.3 ICON plc Omics Based Clinical Trials Introduction
11.4.4 ICON plc Revenue in Omics Based Clinical Trials Business (2017-2022)
11.4.5 ICON plc Recent Developments
11.5 SGS SA
11.5.1 SGS SA Company Details
11.5.2 SGS SA Business Overview
11.5.3 SGS SA Omics Based Clinical Trials Introduction
11.5.4 SGS SA Revenue in Omics Based Clinical Trials Business (2017-2022)
11.5.5 SGS SA Recent Developments
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Company Details
11.6.2 Eli Lilly and Company Business Overview
11.6.3 Eli Lilly and Company Omics Based Clinical Trials Introduction
11.6.4 Eli Lilly and Company Revenue in Omics Based Clinical Trials Business (2017-2022)
11.6.5 Eli Lilly and Company Recent Developments
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Omics Based Clinical Trials Introduction
11.7.4 Pfizer Revenue in Omics Based Clinical Trials Business (2017-2022)
11.7.5 Pfizer Recent Developments
11.8 Covance
11.8.1 Covance Company Details
11.8.2 Covance Business Overview
11.8.3 Covance Omics Based Clinical Trials Introduction
11.8.4 Covance Revenue in Omics Based Clinical Trials Business (2017-2022)
11.8.5 Covance Recent Developments
11.9 Rebus Bio
11.9.1 Rebus Bio Company Details
11.9.2 Rebus Bio Business Overview
11.9.3 Rebus Bio Omics Based Clinical Trials Introduction
11.9.4 Rebus Bio Revenue in Omics Based Clinical Trials Business (2017-2022)
11.9.5 Rebus Bio Recent Developments
11.10 Novo Nordisk
11.10.1 Novo Nordisk Company Details
11.10.2 Novo Nordisk Business Overview
11.10.3 Novo Nordisk Omics Based Clinical Trials Introduction
11.10.4 Novo Nordisk Revenue in Omics Based Clinical Trials Business (2017-2022)
11.10.5 Novo Nordisk Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のオミクス系臨床試験市場インサイト及び予測（介入研究、観察研究、拡張アクセス研究）(Global Omics Based Clinical Trials Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界のオミクス系臨床試験市場インサイト及び予測（介入研究、観察研究、拡張アクセス研究）

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp